News

Can Novo Nordisk’s New CEO Stop Rivals From Taking Over the Anti-Obesity Market?
Danish leader will face a challenging landscape among competitors ...
Novo Nordisk slides further on US competition, new CEO concerns
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Novo Nordisk projects weaker sales as it battles copycat drugs
Novo Nordisk said it expects weaker sales growth of its popular weight-loss drug Wegovy due to competition from copycat drugs ...
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...
Obesity drugmaker Novo Nordisk plunges as it cuts forecasts again
Obesity drugmaker Novo Nordisk on Tuesday cut its full-year sales and operating profit forecasts for the second time this ...
24/7 Wall St.2d
Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?
Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...
Novo Nordisk: Catch That Falling Knife
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Fierce Pharma2d
Novo Nordisk names new CEO as the obesity drugmaker cuts sales, profit outlook
Novo Nordisk has named Maziar Mike Doustdar, currently the company’s EVP of international operations, as the new CEO. Doustdar will succeed Lars Fruergaard Jørgensen, whose surprise abdication was ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...